Dr. Tanner Michael Johanns, MD

Dr. Johanns practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Johanns' NPI, 1619222502, was assigned on July 17, 2012. Dr. Johanns graduated from University of Minnesota Medical School in 2012. Dr. Johanns holds Missouri license 2013039279.

Dr. Johanns' primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Johanns also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Johanns' primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Johanns is also affiliated with Christian Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Johanns to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Johanns practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Johanns' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Johanns is licensed in Missouri.

CMS data shows 2,398 Medicare services from Dr. Johanns across 21 procedure codes in 2024, for 247 Medicare patients. Medicare paid $66,615 for them. Every service was in an office.

CMS counts 247 Medicare patients who saw Dr. Johanns in 2024. The largest group is 65 to 74, with 123 patients. 65% of them have high blood pressure, and 62% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Johanns' median patient age at 68, with 51% women.

In 2024, Dr. Johanns wrote 475 Medicare Part D claims for 85 patients. 91% of them were for generic drugs. CMS names the drug for 265 of them, across 12 drugs with 11 or more claims each, at $5,957 in total drug cost. In 2023, CMS named 405 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Johanns for performance year 2024, reported as part of a group. Dr. Johanns accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Johanns as offering telehealth.

Dmand AI links 48 papers to Dr. Johanns, published from 2010 to 2025. 2021 was the busiest year, with 7. The most frequent topics are Brain Neoplasms, Glioblastoma and CD8-Positive T-Lymphocytes. Dr. Johanns has published most often in Neurooncol Adv. Dr. Johanns' most frequent co-authors are Gavin Peter Dunn, MD, PhD, George Ansstas, MD and Michael R. Chicoine, MD.

Dmand AI links Dr. Johanns to 12 clinical trials, 4 of them phase 1 studies. 6 are still active or recruiting. Conditions studied include Astrocytoma, Glioblastoma and Brain Neoplasms. Washington University School of Medicine sponsors the most, 5. Open Payments lists research payments to Dr. Johanns that name 2 trials.

CMS Open Payments shows 17 general payments to Dr. Johanns from 5 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 70% of the total. Genentech, Inc. paid the most, $9,190. It also lists 2 research payments totaling $130 in 2019, naming 2 clinical trials.

Dr. Johanns graduated from University of Minnesota Medical School in 2012.